首页 | 本学科首页   官方微博 | 高级检索  
检索        

丙种球蛋白辅助治疗小儿川崎病的疗效观察
引用本文:胡淑华.丙种球蛋白辅助治疗小儿川崎病的疗效观察[J].中国医药导刊,2011,13(4):619-620.
作者姓名:胡淑华
作者单位:深圳市龙岗区妇幼保健院儿科,深圳,518172
摘    要:目的:探讨不同剂量丙种球蛋白治疗小儿川崎病的临床疗效。方法:选取我院2006年7月~2009年8月收治的120例川崎病患儿的临床资料,随机分为A、B、C三组,每组40例,三组患者均采用静脉注射丙种球蛋白进行治疗,A组静脉滴注丙种球蛋白2g/kg;B组静脉滴注丙种球蛋白1g/kg×2d;C组静脉滴注丙种球蛋白0.4g/(kg·d)×5d,各组其他治疗相同。观测患儿退热、淋巴结肿大、粘膜充血消退、多形性皮疹及手足症状消退的时间及冠状动脉损害发生率(CAL),并进行统计学分析。结果:A组退热、淋巴结肿大、粘膜充血消退、多形性皮疹及手足症状消退时间较B、C组短,且差异有统计学意义(P<0.05)。B组与C组无明显差异(P>0.05),A、B、C各组CAL无显著性差异(P>0.05),三组均未见明显不良反应。结论:静脉丙种球蛋白2g/kg,单次给药治疗川崎病,能更好的退热,并有效预防冠状动脉并发症的发生,疗效满意值得在临床推广。

关 键 词:川崎病  丙种球蛋白  不同剂量  临床疗效

Clinical Observation of Infantile Kawasaki Disease Treated by Gammaglobulin Adjunctive Therapy
Hu Shu-hua.Clinical Observation of Infantile Kawasaki Disease Treated by Gammaglobulin Adjunctive Therapy[J].Chinese Journal of Medicinal Guide,2011,13(4):619-620.
Authors:Hu Shu-hua
Institution:Hu Shu-hua (Department of Pediatrics,Maternal and Child Health Hospital of Longgang District,Shenzhen,Shenzhen 518172,China)
Abstract:Objective:To investigate the dose immunoglobulin in clinical treatment of children with Kawasaki disease.Metheds:The hospital in My 2006~August 2009 120 patients admitted to the clinical data of children with Kawasaki disease were randomly divided into A,B, C three groups,each group 40 cases,three groups of patients were treated with intravenous globulin treatment,A group of intravenous gamma globulin 2g/kg;B group of intravenous gamma globulin lg/kg×2d;C group of intravenous gamma globulin 0.4g /(kg·d)×5d,the same as other treatment groups.Observed in children with fever,swollen lymph nodes,mucosa congestion subsided and polymorphous skin rash and hand-foot time and remission rate of coronary artery lesions(CAL),and analyzed statistically.Results:A group of fever,swollen lymph nodes,mucosa congestion subsided and polymorphous skin rash and remission time than hand-foot B,C was shorter,and the difference was statistically significant(P<0.05).B group and C group no significant difference(P>0.05),A,B,C CAL in each group no significant difference (P>0.05),.three groups were no obvious adverse reactions.Conclusion:Intravenous gamma globulin 2g/kg,single dose treatment of Kawasaki disease,better cooling,and prevent the occurrence of coronary complications,results were satisfactory in clinical promotion.
Keywords:Kawasaki disease  Gamma globulin  Different doses  Clinical efficacy
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号